Last Updated: September 28, 2026

FELBAMATE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Felbamate, and when can generic versions of Felbamate launch?

Felbamate is a drug marketed by Amneal Pharms, Novitium Pharma, Taro, Alvogen, Ani Pharms, and Zydus Lifesciences. and is included in eight NDAs.

The generic ingredient in FELBAMATE is felbamate. Ten suppliers are listed for this compound. Additional details are available on the felbamate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Felbamate

A generic version of FELBAMATE was approved as felbamate by AMNEAL PHARMS on September 13^th, 2011.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for FELBAMATE?
What are the global sales for FELBAMATE?
What is Average Wholesale Price for FELBAMATE?

Summary for FELBAMATE

US Patents:	0
Applicants:	6
NDAs:	8

US Patents and Regulatory Information for FELBAMATE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	FELBAMATE	felbamate	SUSPENSION;ORAL	202385-001	Dec 16, 2011	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Amneal Pharms	FELBAMATE	felbamate	TABLET;ORAL	201680-002	Sep 13, 2011	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alvogen	FELBAMATE	felbamate	TABLET;ORAL	204595-001	Jan 11, 2016		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	FELBAMATE	felbamate	TABLET;ORAL	208970-001	May 30, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ani Pharms	FELBAMATE	felbamate	TABLET;ORAL	202284-001	Nov 4, 2015	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novitium Pharma	FELBAMATE	felbamate	SUSPENSION;ORAL	211333-001	May 31, 2019	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.